VRTX - Jim Cramer's Take on Vertex: Tackling Opioid Addiction with New Drug in Pipeline | Benzinga

CNBC's Jim Cramer has drawn investors' attention to Vertex Pharmaceuticals (NASDAQ: VRTX), a biotechnology company currently in the late stages of developing a non-opioid drug to treat acute pain. 

The company's potential candidate, known as VX-548, is being positioned to address the critical issue of opioid addiction.

Vertex Pharmaceuticals primarily generates its revenue from Trikafta, a cystic fibrosis treatment. 

However, their strategic shift towards addressing the pain management market has sparked excitement within the investment community. Cramer emphasized the significance of Full story available on Benzinga.com